|
KMID : 1102220220410000074
|
|
Kidney Research and Clinical Practice
2022 Volume.41 No. 0 p.74 ~ p.88
|
|
|
Adenosine receptors as emerging therapeutic targets for diabetic kidney disease
|
|
Pak Eun-Seon
Cha Jin-Joo
Cha Dae-Ryong
Kanasaki Keizo
Ha Hun-Joo
|
|
|
Abstract
|
|
|
|
Diabetic kidney disease (DKD) is now a pandemic worldwide, and novel therapeutic options are urgently required. Adenosine, an adenosine triphosphate metabolite, plays a role in kidney homeostasis through interacting with four types of adenosine receptors (ARs): A1AR, A2AAR, A2BAR, and A3AR. Increasing evidence highlights the role of adenosine and ARs in the development and progression of DKD: 1) increased adenosine in the plasma and urine of diabetics with kidney injury, 2) increased expression of each of the ARs in diabetic kidneys, 3) the protective effect of coffee, a commonly ingested nonselective AR antagonist, on DKD, and 4) the protective effect of AR modulators in experimental DKD models. We propose AR modulators as a new therapeutic option to treat DKD. Detailed mechanistic studies on the pharmacology of AR modulators will help us to develop effective first-in-class AR modulators against DKD.
|
|
|
KEYWORD
|
|
|
Adenosine, Purinergic P1 receptors, Purinergic P1 receptor agonists, Purinergic P1 receptor antagonists, Diabetic kidney disease, Fibrosis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
   
|
|